Other News To Note
• Alnylam Pharmaceuticals Inc., of Cambridge, Mass., formed a collaboration with GlaxoSmithKline plc, of London, focused on the use of Alnylam's VaxiRNA technology to produce certain GSK vaccine products. VaxiRNA is an RNAi technology for the enhanced production of viruses used to manufacture vaccine products. The GSK collaboration is focused initially on influenza vaccine production in cell culture systems, with an option for applications in two additional vaccine products.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST